Hashim U Ahmed

List of Publications by Year in Descending Order

350 papers	12,127 citations	54 h-index	102 g-index
403 ext. papers	14,829 ext. citations	5.3 avg, IF	6.44 L-index

#	Paper	IF	Citations
350	Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study.. *Diagnostics*, **2022**, 12,	3.8	2
349	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.. *European Urology*, **2022**,	10.2	3
348	A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer.. *European Urology Open Science*, **2022**, 36, 9-18	0.9	0
347	The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.. *PLoS ONE*, **2022**, 17, e0259672	3.7	0
346	Impact of Work-Related Chronic Low Back Pain on Functional Performance and Physical Capabilities in Women and Men: A Sex-Wise Comparative Study.. *BioMed Research International*, **2022**, 2022, 6307349	3	0
345	Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.. *Lancet Oncology, The*, **2022**, 23, 428-438	21.7	3
344	Adjusting for verification bias in diagnostic accuracy measures when comparing multiple screening tests - an application to the IP1-PROSTAGRAM study.. *BMC Medical Research Methodology*, **2022**, 22, 70	4.7	0
343	Evaluating Patterns and Factors Related to Sleep Disturbances in Prostate Cancer Patients. *Healthcare (Switzerland)*, **2022**, 10, 832	3.4	0
342	Reply to Francesco Montorsi, Armando Stabile, Elio Mazzone, Giorgio Gandaglia, and Alberto Briganti's Letter to the Editor re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with	10.2	1
341	Clinical Translation of Positive Metastases Identified on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging in the Management of De Novo Synchronous Oligometastatic Prostate Cancer. *European Urology Focus*, **2021**, 7, 951-954	5.1	1
340	Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial. *European Urology*, **2021**,	10.2	1
339	Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study. *BMJ Open*, **2021**, 11, e048996	3	1
338	The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer. *Frontiers in Artificial Intelligence*, **2021**, 4, 769582	3	0
337	Template Mapping Biopsies: An Overview of Technique and Results **2021**, 145-159		
336	Safety and adverse events of urgent elective surgery during COVID-19 within three UK hospitals. *British Journal of Surgery*, **2021**, 108, e51-e52	5.3	0
335	The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy. *European Urology Focus*, **2021**, 7, 1027-1034	5.1	7
334	A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 596-611	6.2	19

333	Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study. *JAMA Oncology*, **2021**, 7, 395-402	13.4	27
332	COVID-19: are the elderly prepared for virtual healthcare?. *BMJ Health and Care Informatics*, **2021**, 28,	2.6	1
331	Radical Treatment Without Cure: Decision-making in Oligometastatic Prostate Cancer. *European Urology*, **2021**, 79, 558-560	10.2	3
330	Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer. *Journal of Urology*, **2021**, 205, 1090-1099	2.5	5
329	A Comparison of Prostate Cancer Detection between Visual Estimation (Cognitive Registration) and Image Fusion (Software Registration) Targeted Transperineal Prostate Biopsy. *Journal of Urology*, **2021**, 205, 1075-1081	2.5	8
328	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 1120-1128	6.2	2
327	Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 830.e1-830.e8	2.8	1
326	Outcomes of the RAFT trial: robotic surgery after focal therapy. *BJU International*, **2021**, 128, 504-510	5.6	3
325	Prostate cancer in transgender women: what does a urologist need to know?. *BJU International*, **2021**,	5.6	4
324	Review article: MRI-targeted biopsies for prostate cancer diagnosis and management. *World Journal of Urology*, **2021**, 39, 57-63	4	5
323	Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. *World Journal of Urology*, **2021**, 39, 1115-1119	4	8
322	Role of multiparametric prostate MRI in the management of prostate cancer. *World Journal of Urology*, **2021**, 39, 651-659	4	8
321	False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. *European Urology*, **2021**, 79, 20-29	10.2	3
320	Peritumoral Delivery of Docetaxel-TIPS Microparticles for Prostate Cancer Adjuvant Therapy. *Advanced Therapeutics*, **2021**, 4, 2000179	4.9	1
319	Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. *BJU International*, **2021**, 127, 304-306	5.6	15
318	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. *European Urology Focus*, **2021**, 7, 301-308	5.1	3
317	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 567-574	6.2	4
316	Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. *BMJ Open*, **2021**, 11, e042953	3	6

315	B2B: Prostate Cancer. *Soci Internationale Dfurologie Journal*, **2021**, 2, S30-S50	0.1	
314	PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study. *Contemporary Clinical Trials*, **2021**, 107, 106485	2.3	0
313	Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography-The IP1-PROSTAGRAM Study-Reply. *JAMA Oncology*, **2021**, 7, 1575-1576	13.4	2
312	Feasibility of Comparative Health Research Outcome of Novel Surgery in prostate cancer (IP4-CHRONOS): statistical analysis plan for the randomised feasibility phase of the CHRONOS study. *Trials*, **2021**, 22, 547	2.8	
311	Erectile Function Post Prostate Biopsy: A Systematic Review and Meta-analysis. *Urology*, **2021**, 155, 1-8	1.6	2
310	Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis. *Prostate Cancer and Prostatic Diseases*, **2021**,	6.2	4
309	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. *BJU International*, **2021**, 128, 440-450	5.6	4
308	Computer-aided diagnosis of prostate cancer using multiparametric MRI and clinical features: A patient-level classification framework. *Medical Image Analysis*, **2021**, 73, 102153	15.4	8
307	AutoProstate: Towards Automated Reporting of Prostate MRI for Prostate Cancer Assessment Using Deep Learning. *Cancers*, **2021**, 13,	6.6	3
306	What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort. *European Urology*, **2020**, 78, 163-170	10.2	28
305	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. *European Radiology*, **2020**, 30, 5404-5416	8	80
304	The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. *European Urology*, **2020**, 78, 155-160	10.2	8
303	Understanding virtual urology clinics: a systematic review. *BJU International*, **2020**, 126, 536-546	5.6	9
302	Simulation in Urological Training and Education (SIMULATE): Protocol and curriculum development of the first multicentre international randomized controlled trial assessing the transferability of simulation-based surgical training. *BJU International*, **2020**, 126, 202-211	5.6	13
301	Cytoreductive cryotherapy for newly diagnosed oligometastatic hormone-sensitive prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 537-538	6.2	1
300	All change in the prostate cancer diagnostic pathway. *Nature Reviews Clinical Oncology*, **2020**, 17, 372-381	19.4	20
299	Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 232-243	6.2	9
298	Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. *BJU International*, **2020**, 125, 853-860	5.6	9

297	MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients. *International Journal of Radiation Oncology Biology Physics*, **2020**, 107, 126-135	4	14
296	Targeted and Systematic Biopsy for the Diagnosis and Management of Prostate Cancer - A Case for Lesion Targeted-Only Biopsies. *Clinical Oncology*, **2020**, 32, 136-143	2.8	0
295	Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy. *Journal of Urology*, **2020**, 204, 950-955	2.5	0
294	Initial experience of the adjuvant treatments to the local tumor for metastatic prostate cancer: Assessment of novel treatment algorithms, a multicenter, phase II randomized controlled trial (IP2-ATLANTA).. *Journal of Clinical Oncology*, **2020**, 38, TPS5600-TPS5600	2.2	1
293	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. *European Urology*, **2020**, 78, 402-414	10.2	65
292	Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial. *Journal of Urology*, **2020**, 203, 100-107	2.5	4
291	Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound. *Journal of Urology*, **2020**, 203, 734-742	2.5	16
290	Evaluating the Trade-Offs Men with Localized Prostate Cancer Make between the Risks and Benefits of Treatments: The COMPARE Study. *Journal of Urology*, **2020**, 204, 273-280	2.5	15
289	A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging. *Journal of Urology*, **2020**, 204, 1195-1201	2.5	2
288	Cytoreductive treatment strategies for de novo metastatic prostate cancer. *Nature Reviews Clinical Oncology*, **2020**, 17, 168-182	19.4	19
287	Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer. *BJU International*, **2020**, 125, 49-55	5.6	18
286	Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial. *BJU International*, **2020**, 125, 391-398	5.6	5
285	Survival in Oligometastatic Prostate Cancer-A New Dawn or the Will Rogers Phenomenon?. *JAMA Oncology*, **2020**, 6, 185-186	13.4	10
284	Re: Antonio C. Westphalen, Charles E. McCulloch, Jordan M. Anaokar, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology 2020;296:76-84: Can the Positive Predictive Value of Prostate MRI in Correlation with Biopsy Findings be Interpreted	6.7	1
283	Autonomous surgery in the era of robotic urology: friend or foe of the future surgeon?. *Nature Reviews Urology*, **2020**, 17, 643-649	5.5	7
282	Targeting the cancer lesion, not the whole prostate. *Translational Andrology and Urology*, **2020**, 9, 1518-1525	2.3	3
281	A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer. *Translational Andrology and Urology*, **2020**, 9, 1535-1545	2.3	8
280	Value of systematic sampling in an mp-MRI targeted prostate biopsy strategy. *Translational Andrology and Urology*, **2020**, 9, 1501-1509	2.3	3

279	Rethinking prostate cancer screening: could MRI be an alternative screening test?. *Nature Reviews Urology*, **2020**, 17, 526-539	5.5	5
278	Effect of Chronic Ankle Sprain on Pain, Range of Motion, Proprioception, and Balance among Athletes. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	11
277	Re: Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol 2020;77:501-7. *European Urology*, **2020**, 78, e106-e107	10.2	1
276	A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists. *Scientific Reports*, **2020**, 10, 17177	4.9	1
275	Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. *European Urology Oncology*, **2020**, 3, 582-593	6.7	12
274	Use of Imaging to Optimise Prostate Cancer Tumour Volume Assessment for Focal Therapy Planning. *Current Urology Reports*, **2020**, 21, 38	2.9	4
273	A prospective analysis of robotic targeted MRI-US fusion prostate biopsy using the centroid targeting approach. *Journal of Robotic Surgery*, **2020**, 14, 69-74	2.9	15
272	A Multicentre Analysis of the Detection of Clinically Significant Prostate Cancer Following Transperineal Image-fusion Targeted and Nontargeted Systematic Prostate Biopsy in Men at Risk. *European Urology Oncology*, **2020**, 3, 262-269	6.7	13
271	Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. *Contemporary Clinical Trials*, **2020**, 93, 105999	2.3	9
270	Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. *European Urology*, **2020**, 78, 503-511	10.2	16
269	An Exploratory Study of Dose Escalation Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer. *Journal of Endourology*, **2020**, 34, 641-646	2.7	2
268	Efficacy of Combination Therapies on Neck Pain and Muscle Tenderness in Male Patients with Upper Trapezius Active Myofascial Trigger Points. *BioMed Research International*, **2020**, 2020, 9361405	3	6
267	Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. *World Journal of Urology*, **2019**, 37, 2147-2153	4	15
266	Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105. *European Urology*, **2019**, 76, e63-e64	10.2	
265	Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists. *European Radiology*, **2019**, 29, 4754-4764	8	37
264	Targeted biopsy of the prostate: does this result in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon?. *BJU International*, **2019**, 124, 643	5.6	8
263	Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. *European Urology*, **2019**, 76, 27-30	10.2	35
262	VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient. *Radiology*, **2019**, 291, 391-397	20.5	26

261	MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. *International Journal of Radiation Oncology Biology Physics*, **2019**, 104, 1045-1053	4	15
260	Late toxicity described using patient reported outcomes measures (PROMS) in men treated with salvage radiation following primary high intensity focal ultrasound (HIFU) for localized prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 131-131	2.2	1
259	The effects of testosterone replacement therapy on the prostate: a clinical perspective. *F1000Research*, **2019**, 8,	3.6	3
258	MP01-03 REZŪM WATER VAPOUR ABLATION THERAPY FOR BENIGN PROSTATIC HYPERPLASIA: INITIAL RESULTS FROM THE UNITED KINGDOM. *Journal of Urology*, **2019**, 201,	2.5	2
257	Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. *BJU International*, **2019**, 124, 431-440	5.6	48
256	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer. *BMC Medical Imaging*, **2019**, 19, 90	2.9	6
255	A novel adjuvant drug-device combination tissue scaffold for radical prostatectomy. *Drug Delivery*, **2019**, 26, 1115-1124	7	4
254	A prospective clinical, cost and environmental analysis of a clinician-led virtual urology clinic. *Annals of the Royal College of Surgeons of England*, **2019**, 101, 30-34	1.4	24
253	Multi-parametric MRI zone-specific diagnostic model performance compared with experienced radiologists for detection of prostate cancer. *European Radiology*, **2019**, 29, 4150-4159	8	5
252	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. *European Urology*, **2019**, 76, 98-105	10.2	63
251	Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging. *European Radiology*, **2019**, 29, 3159-3169	8	22
250	The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification. *European Urology*, **2019**, 75, 733-740	10.2	40
249	Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91. *European Urology*, **2019**, 75, e21-e22	10.2	1
248	Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning. *Prostate Cancer and Prostatic Diseases*, **2019**, 22, 261-267	6.2	9
247	Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasound-guided prostate interventions. *Medical Physics*, **2018**, 45, 1408-1414	4.4	6
246	Three-dimensional printing in robot-assisted radical prostatectomy - an Idea, Development, Exploration, Assessment, Long-term follow-up (IDEAL) Phase 2a study. *BJU International*, **2018**, 122, 360-361	5.6	25
245	Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2. *European Urology*, **2018**, 73, e151-e152	10.2	
244	Re: Predictors of Infectious Complications After Targeted Prophylaxis for Prostate Needle Biopsy. *European Urology*, **2018**, 74, 523-524	10.2	4

243	The CADMUS trial - Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. *Contemporary Clinical Trials*, **2018**, 66, 86-92	2.3	9
242	A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 67-76	2.8	17
241	National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. *BJU International*, **2018**, 122, 13-25	5.6	78
240	Re: Effect of Prior Focal Therapy on Perioperative, Oncologic and Functional Outcomes of Salvage Robotic Assisted Radical Prostatectomy: I. Nunes-Silva, E. Barret, V. Srougi, M. Baghdadi, P. Capogrosso, S. Garcia-Barreras, S. Kanso, R. Tourinho-Barbosa, A. Carneiro, R. Sanchez-Salas, F. Rozet, M. Galiano and X. Cathelineau. J Urol 2017;198:1069-1076. *Journal of Urology*, **2018**, 199, 1634-1635	2.5	
239	Performance characteristics of multiparametric-MRI at a non-academic hospital using transperineal template mapping biopsy as a reference standard. *International Journal of Surgery Open*, **2018**, 10, 66-71	0.9	2
238	Impact of Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. *Journal of Nuclear Medicine*, **2018**, 59, 89-92	8.9	54
237	Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). *European Urology*, **2018**, 73, 23-30	10.2	105
236	Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. *Urologic Oncology: Seminars*	2.8	9
235	The British Urology Researchers in Surgical Training (BURST) Research Collaborative: an alternative research model for carrying out large scale multi-centre urological studies. *BJU International*, **2018**, 121, 6-9	5.6	7
234	Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates. *Prostate*, **2018**, 78, 1229-1237	4.2	7
233	Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 175-186	6.2	21
232	Accuracy of Transperineal Targeted Prostate Biopsies, Visual Estimation and Image Fusion in Men Needing Repeat Biopsy in the PICTURE Trial. *Journal of Urology*, **2018**, 200, 1227-1234	2.5	28
231	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. *BJU International*, **2018**, 122, 970-977	5.6	10
230	Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI. *British Journal of Radiology*, **2018**, 91, 20170645	3.4	17
229	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. *Health Technology Assessment*, **2018**, 22, 1-176	4.4	46
228	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. *Health Technology Assessment*, **2018**, 22, 1-96	4.4	18
227	Prostate imaging features that indicate benign or malignant pathology on biopsy. *Translational Andrology and Urology*, **2018**, 7, S420-S435	2.3	17
226	High-intensity Focused Ultrasound of the Prostate **2018**, 1567-1579		

225	Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 529.e11-529.e22	2.8	12
224	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK. *BMJ Open*, **2018**, 8, e024941	2	8
223	Inter-site Variability in Prostate Segmentation Accuracy Using Deep Learning. *Lecture Notes in Computer Science*, **2018**, 506-514	0.9	26
222	UK medical students' perceptions, attitudes, and interest toward medical leadership and clinician managers. *Advances in Medical Education and Practice*, **2018**, 9, 119-124	1.5	10
221	Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study. *Journal of Urology*, **2018**, 200, 1235-1240	2.5	37
220	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. *European Urology*, **2018**, 74, 422-429	10.2	122
219	Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy. *IEEE Transactions on Biomedical Engineering* , **2017**, 64, 946-958	5	11
218	Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet, The*, **2017**, 389, 815-822	40	1485
217	Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 150.e1-150.e7	2.8	26
216	Re: Limitations of Elastography Based Prostate Biopsy: J. Schiffmann, M. Grindei, Z. Tian, D.-J. Yassin, T. Steinwender, S.-R. Leyh-Bannurah, M. Randazzo, M. Kwiatkowski, P. I. Karakiewicz, P. Hammerer and L. Manka J Urol 2016;195:1731-1736. *Journal of Urology*, **2017**, 197, 263-264	2.5	
215	Beam distortion due to gold fiducial markers during salvage high-intensity focused ultrasound in the prostate. *Medical Physics*, **2017**, 44, 679-693	4.4	6
214	Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. *BJU International* , **2017**, 120, 246-256	5.6	28
213	A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis. *Computerized Medical Imaging and Graphics*, **2017**, 56, 1-10	7.6	15
212	Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. *Prostate Cancer and Prostatic Diseases*, **2017**, 20, 311-317	6.2	40
211	The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. *British Journal of Cancer*, **2017**, 116, 1159-1165	8.7	71
210	Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. *Prostate Cancer and Prostatic Diseases*, **2017**, 20, 294-299	6.2	61
209	Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome. *Urologic Clinics of North America*, **2017**, 44, 575-585	2.9	9
208	An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements. *APL Bioengineering*, **2017**, 1, 016101	6.6	9

207	The death of ink: the value of typing skills as an addition to the medical school curriculum. *Advances in Medical Education and Practice*, **2017**, 8, 701-702	1.5	2
206	The ability of free to total prostate-specific antigen and prostate-specific antigen density to detect clinically significant prostate cancer in men undergoing transperineal template biopsy. *Journal of Clinical Urology*, **2017**, 10, 529-534	0.2	1
205	Intraoperative Organ Motion Models with an Ensemble of Conditional Generative Adversarial Networks. *Lecture Notes in Computer Science*, **2017**, 368-376	0.9	7
204	Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways. *Expert Review of Anticancer Therapy*, **2017**, 17, 1159-1168	3.5	3
203	MP33-20 THE SMARTTARGET BIOPSY TRIAL: A PROSPECTIVE PAIRED BLINDED TRIAL WITH RANDOMISATION TO COMPARE VISUAL-ESTIMATION AND IMAGE-FUSION TARGETED PROSTATE BIOPSIES. *Journal of Urology*, **2017**, 197,	2.5	4
202	Focal Therapy for Prostate Cancer **2017**, 133-149		
201	PD56-08 THE PART TRIAL - A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER EARLY DATA FROM THE FEASIBILITY STUDY. *Journal of Urology*, **2017**, 197,	2.5	3
200	MP38-07 SHOULD WE AIM FOR THE CENTRE OF AN MRI PROSTATE LESION? CORRELATION BETWEEN MPMRI AND 3-DIMENSIONAL 5MM TRANSPERINEAL PROSTATE MAPPING BIOPSIES FROM THE PROMIS TRIAL. *Journal of Urology*, **2017**, 197,	2.5	1
199	Diagnostic accuracy of the PROMIS study - Authors' reply. *Lancet, The*, **2017**, 390, 362	40	3
198	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. *Annals of Oncology*, **2017**, 28, 2472-2480	10.3	35
197	Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 30.e9-30.e15	2.8	40
196	The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial. *Journal of Urology*, **2017**, 197, 1006-1013	2.5	14
195	"Textural analysis of multiparametric MRI detects transition zone prostate cancer". *European Radiology*, **2017**, 27, 2348-2358	8	58
194	Complications After Systematic, Random, and Image-guided Prostate Biopsy. *European Urology*, **2017**, 71, 353-365	10.2	225
193	Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer. *Journal of Urology*, **2017**, 197, 647-654	2.5	46
192	Identifying and Characterizing the Index Lesion. *Current Clinical Urology*, **2017**, 105-113		
191	Does true Gleason pattern 3 merit its cancer descriptor?. *Nature Reviews Urology*, **2016**, 13, 541-8	5.5	15
190	INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer. *BMC Cancer*, **2016**, 16, 816	4.8	26

189	The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial. *Prostate Cancer and Prostatic Diseases*, **2016**, 19, 258-63	6.2	7
188	Multiparametric ultrasound in the diagnosis of prostate cancer. *Current Opinion in Urology*, **2016**, 26, 114-9	2.8	13
187	Transperineal Magnetic Resonance Imaging-targeted Biopsy versus Transperineal Template Prostate Mapping Biopsy in the Detection of Localised Radio-recurrent Prostate Cancer. *Clinical Oncology*, **2016**, 28, 568-76	2.8	13
186	MP53-03 TRANSPERINEAL MRI VISUALLY-TARGETED PROSTATE BIOPSIES COMPARED TO TEMPLATE MAPPING BIOPSY IN 534 MEN REQUIRING FURTHER RISK STRATIFICATION. *Journal of Urology*, **2016**, 195,	2.5	1
185	The challenging landscape of medical device approval in localized prostate cancer. *Nature Reviews Urology*, **2016**, 13, 91-8	5.5	5
184	Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. *European Urology*, **2016**, 70, 668-674	10.2	45
183	Modeling Cryotherapy Ice Ball Dimensions and Isotherms in a Novel Gel-based Model to Determine Optimal Cryo-needle Configurations and Settings for Potential Use in Clinical Practice. *Urology*, **2016**, 91, 234-40	1.6	27
182	Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. *Brachytherapy*, **2016**, 15, 296-305	2.4	16
181	The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies. *Journal of Urology*, **2016**, 195, 1403-1408	2.5	18
180	The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. *European Urology*, **2016**, 69, 844-51	10.2	33
179	The PROMIS study: A paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA.. *Journal of Clinical Oncology*, **2016**, 34, 5000-5000	2.2	9
178	Template Mapping Biopsies: An Overview of Technique and Results **2016**, 111-123		
177	High-Intensity Focused Ultrasound for Prostate Cancer **2016**, 139-151		
176	Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer. *BJU International*, **2016**, 118, 384-90	5.6	17
175	MP18-08 FOCAL HIFU FOR TREATMENT OF LOCALISED PROSTATE CANCER: A MULTI-CENTRE REGISTRY EXPERIENCE. *Journal of Urology*, **2016**, 195,	2.5	2
174	MP18-20 THE NANOKNIFE ELECTROPORATION ABLATION TRIAL (NEAT): A PROSPECTIVE DEVELOPMENT STUDY. *Journal of Urology*, **2016**, 195,	2.5	1
173	Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy. *Radiotherapy and Oncology*, **2016**, 119, 104-10	5.3	10
172	PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure. *Prostate Cancer and Prostatic Diseases*, **2016**, 19, 311-6	6.2	11

171	F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies. *American Journal of Roentgenology*, **2016**, 207, 1297-1306	5.4	1
170	Focal therapy in prostate cancer: A review of seven common controversies. *Cancer Treatment Reviews*, **2016**, 51, 27-34	14.4	21
169	A randomized controlled trial to investigate magnetic resonance imaging-targeted biopsy as an alternative diagnostic strategy to transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 156-7	2.8	
168	The FORECAST study - Focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer. *Contemporary Clinical Trials*, **2015**, 44, 175-186	2.3	17
167	What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies. *Urology*, **2015**, 86, 544-51	1.6	1
166	Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 424.e9-16	2.8	36
165	Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images. *Prostate Cancer and Prostatic Diseases*, **2015**, 18, 128-36	6.2	48
164	Histological outcomes after focal high-intensity focused ultrasound and cryotherapy. *World Journal of Urology*, **2015**, 33, 955-64	4	23
163	Zone-specific logistic regression models improve classification of prostate cancer on multi-parametric MRI. *European Radiology*, **2015**, 25, 2727-37	8	26
162	Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy. *International Journal of Radiation Oncology Biology Physics*, **2015**, 92, 787-93	4	26
161	Microstructural characterization of normal and malignant human prostate tissue with vascular, extracellular, and restricted diffusion for cytometry in tumours magnetic resonance imaging. *Investigative Radiology*, **2015**, 50, 218-27	10.1	99
160	Focal Therapy of Prostate Cancer Using Irreversible Electroporation. *Techniques in Vascular and Interventional Radiology*, **2015**, 18, 147-52	2.6	11
159	Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. *Tumor Biology*, **2015**, 36, 9137-46	2.9	45
158	Population-based prediction of subject-specific prostate deformation for MR-to-ultrasound image registration. *Medical Image Analysis*, **2015**, 26, 332-44	15.4	27
157	Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. *European Urology*, **2015**, 68, 927-36	10.2	126
156	Logistic regression model for diagnosis of transition zone prostate cancer on multi-parametric MRI. *European Radiology*, **2015**, 25, 523-32	8	32
155	Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. *European Urology*, **2015**, 68, 8-19	10.2	314
154	A novel randomised controlled trial design in prostate cancer. *BJU International*, **2015**, 116, 6-8	5.6	2

153	The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update. *European Urology Focus*, **2015**, 1, 212-214	5.1	
152	What tumours should we treat with focal therapy based on risk category, grade, size and location?. *Current Opinion in Urology*, **2015**, 25, 212-9	2.8	10
151	Methodological considerations in assessing the utility of imaging in early prostate cancer. *Current Opinion in Urology*, **2015**, 25, 536-42	2.8	7
150	A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer. *Current Opinion in Urology*, **2015**, 25, 483-9	2.8	12
149	Focal or Multifocal Therapy in Prostate Cancer: New Technologies and Strategies **2015**, 75-85		
148	Words of Wisdom. Re: Multiparametric Magnetic Resonance Imaging (MRI) and Subsequent MRI/Ultrasonography Fusion-guided Biopsy Increase the Detection of Anteriorly Located Prostate Cancers. *European Urology*, **2015**, 67, 1187-8	10.2	
147	Clinical utility of transperineal template-guided mapping biopsy of the prostate after negative magnetic resonance imaging-guided transrectal biopsy. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 329.e7-11	2.8	10
146	PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. *Contemporary Clinical Trials*, **2015**, 42, 26-40	2.3	68
145	Identifying the index lesion with template prostate mapping biopsies. *Journal of Urology*, **2015**, 193, 1185-90	2.5	12
144	Technological aspects of delivering cryotherapy for prostate cancer. *Expert Review of Medical Devices*, **2015**, 12, 183-90	3.5	6
143	Re: Morgan R. Pokorny, Maarten de Rooij, Earl Duncan, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66:22-9. *European Urology*, **2015**, 67, e52-3	10.2	
142	Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. *European Urology*, **2015**, 67, 771-7	10.2	163
141	Re: Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study: J. E. Thompson, D. Moses, R. Shnier, P. Brenner, W. Delprado, L. Ponsky, M. Pulbrook, M. Böhm, A.-M. Haynes, A. Hayen and P. D. Stricker J Urol 2014;192:67-74. *Journal of Urology*, **2015**, 193, 735-6; discussion 736	2.5	2
140	The Concept of the Index Lesion **2015**, 9-17		1
139	Does focal high-intensity focused ultrasound have a role in treating localized prostate cancer in the elderly?. *Journal of Clinical Oncology*, **2015**, 33, 133-133	2.2	1
138	The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level--can it rule out clinically significant prostate cancer?. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 45.e17-22	2.8	99
137	Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. *Current Urology Reports*, **2014**, 15, 390	2.9	21
136	Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. *European Urology*, **2014**, 65, 1023-31	10.2	98

135	Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy. *Urology*, **2014**, 84, 1157-62	1.6	24
134	Re: Jarow et al.: Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop (Urology 2014;83:975-979). *Urology*, **2014**, 84, 732-3	1.6	3
133	Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2014**, 17, 343-7	6.2	97
132	Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 741-7	2.8	24
131	A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). *Contemporary Clinical Trials*, **2014**, 39, 57-65	2.3	45
130	Introduction--Targeting the lesion, not the organ. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 901-2	2.8	5
129	Prostate cancer: Melbourne consensus-noble but misguided. *Nature Reviews Urology*, **2014**, 11, 250-1	5.5	2
128	Can we deliver randomized trials of focal therapy in prostate cancer?. *Nature Reviews Clinical Oncology*, **2014**, 11, 482-91	19.4	47
127	Re: Tumor target volume for focal therapy of prostate cancer--does multiparametric magnetic resonance imaging allow for a reliable estimation?: F. Cornud, G. Khoury, N. Bouazza, F. Beuvon, M. Peyromaure, T. Flam, M. Zerbib, P. Legmann and N. B. Delongchamps. J Urol 2014; 191: 1272-1279. *Journal of Urology*, **2014**, 192, 1297-8	2.5	3
126	Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. *European Urology*, **2014**, 66, 12-9	10.2	28
125	Defining the level of evidence for technology adoption in the localized prostate cancer pathway. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 924-30	2.8	4
124	MP62-03 HIGH-INTENSITY FOCUSSED ULTRASOUND IN THE TREATMENT OF LOCALISED PROSTATE CANCER: FOCAL SALVAGE TRANSITION RATES. *Journal of Urology*, **2014**, 191,	2.5	1
123	Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. *Prostate Cancer and Prostatic Diseases*, **2014**, 17, 40-6	6.2	81
122	Novel Therapies for Localized Prostate Cancer **2014**, 191-210		
121	Focal cryotherapy of localized prostate cancer: a systematic review of the literature. *Expert Review of Anticancer Therapy*, **2014**, 14, 1337-47	3.5	36
120	Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis. *BMJ Open*, **2014**, 4, e004895	3	20
119	Are policy decisions on surgical procedures informed by robust economic evidence? A systematic review. *International Journal of Technology Assessment in Health Care*, **2014**, 30, 381-93	1.8	6
118	Health technology assessment in evolution - focal therapy in localised prostate cancer. *Expert Review of Anticancer Therapy*, **2014**, 14, 1359-67	3.5	7

117	Biopsy strategies for selecting patients for focal therapy for prostate cancer. *Current Opinion in Urology*, **2014**, 24, 209-17	2.8	11
116	Focal therapy will become a standard option for selected men with localized prostate cancer. *Journal of Clinical Oncology*, **2014**, 32, 3680-1	2.2	13
115	Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study. *European Urology*, **2014**, 65, 628-34	10.2	45
114	The PICTURE study -- prostate imaging (multi-parametric MRI and Prostate HistoScanning) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation. *Contemporary Clinical Trials*, **2014**, 37, 69-83	2.3	43
113	Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. *European Urology*, **2014**, 65, 1078-83	10.2	132
112	Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer. *Journal of Urology*, **2014**, 191, 1764-9	2.5	22
111	The role of focal therapy in the management of localised prostate cancer: a systematic review. *European Urology*, **2014**, 66, 732-51	10.2	229
110	Role of Imaging as an Adjunct or Replacement for Biopsy: European Experience **2013**, 337-349		
109	Systematic review of complications of prostate biopsy. *European Urology*, **2013**, 64, 876-92	10.2	564
108	Focal therapy for prostate cancer: rationale and treatment opportunities. *Clinical Oncology*, **2013**, 25, 461-73	2.8	35
107	A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study. *Contemporary Clinical Trials*, **2013**, 36, 68-80	2.3	54
106	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 281-4	2.8	25
105	Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer. *World Journal of Urology*, **2013**, 31, 1361-8	4	13
104	Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system. *BJU International*, **2013**, 112, 594-601	5.6	42
103	Prostate cancer: Time for active surveillance of intermediate-risk disease?. *Nature Reviews Urology*, **2013**, 10, 6-8	5.5	7
102	Prostate Cancer UK: the Blue Skies Forum. *Trends in Urology & Men's Health*, **2013**, 4, 39-43	0.3	1
101	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. *Journal of Magnetic Resonance Imaging*, **2013**, 37, 48-58	5.6	106
100	Re: Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy: M. Han, D. Chang, C. Kim, B. J. Lee, Y. Zuo, H.-J. Kim, D. Petrisor, B. Trock, A. W. Partin, R. Rodriguez, H. B. Carter, M. Allaf, J. Kim and D. Stoianovici. J Urol 2012; 188: 2404-2409. *Journal of Urology*, **2013**, 190, 363-4	2.5	1

99	553 FIVE YEAR ONCOLOGICAL OUTCOMES FOLLOWING WHOLE-GLAND PRIMARY HIFU FROM THE UK INDEPENDENT HIFU REGISTRY. *Journal of Urology*, **2013**, 189,	2.5	1
98	Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. *Journal of Urology*, **2013**, 189, 860-6	2.5	157
97	Prostate cancer screening and the management of clinically localized disease. *BMJ, The*, **2013**, 346, f325	5.9	53
96	Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. *Radiology*, **2013**, 268, 761-9	20.5	143
95	Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. *BJU International*, **2013**, 111, 1011-1013	5.6	2
94	Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. *Cancer*, **2013**, 119, 4052-3	6.4	3
93	Efficacy of Muscle Energy Technique in Combination with Strain-counterstrain Technique on Deactivation of Trigger Point Pain. *Indian Journal of Physiotherapy and Occupational Therapy*, **2013**, 7, 118	2	2
92	Selective Minimally Invasive Therapy in Older Patients for Localized Prostate Cancer: A Way to Mitigate Harm and Retain Benefit? **2013**, 131-151		
91	Standardisation of Focal Therapy Protocols **2013**, 255-269		
90	Identifying the Index Lesion **2013**, 73-80		
89	MR to ultrasound registration for image-guided prostate interventions. *Medical Image Analysis*, **2012**, 16, 687-703	15.4	123
88	Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. *BJU International*, **2012**, 109, 1636-47	5.6	88
87	Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. *BJU International*, **2012**, 110, 517-23	5.6	47
86	A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. *BJU International*, **2012**, 110, 812-20	5.6	72
85	Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. *Lancet Oncology, The*, **2012**, 13, 622-32	21.7	292
84	Focal HIFU for prostate cancer Authors' reply. *Lancet Oncology, The*, **2012**, 13, e284	21.7	1
83	Focal therapy will become standard treatment for localized prostate cancer: pro. *Journal of Urology* , **2012**, 187, 792-4	2.5	6
82	Transvaginal Cystectomy for Complete Bladder Prolapse. *British Journal of Medical and Surgical Urology*, **2012**, 5, 251-253		

81	1441 THE ROLE OF MULTIPARAMETRIC MRI IN MEN WITH NEGATIVE BIOPSY AND ELEVATED PSA - CAN IT RULE OUT CLINICALLY SIGNIFICANT DISEASE?. *Journal of Urology*, **2012**, 187,	2.5	1
80	General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. *BJU International*, **2012**, 110, E429; author reply E429-30	5.6	
79	Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?. *Lancet Oncology, The*, **2012**, 13, e509-17	21.7	119
78	The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. *Journal of Urology*, **2012**, 188, 974-80	2.5	75
77	Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. *Journal of Urology*, **2012**, 188, 762-7	2.5	77
76	Trends in pathologic outcomes after introduction of active surveillance in the UK: implication for focal therapy. *Prostate*, **2012**, 72, 1464-8	4.2	4
75	Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. *Cancer*, **2012**, 118, 3071-8	6.4	41
74	Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. *Cancer*, **2012**, 118, 4148-55	6.4	76
73	Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. *BJU International*, **2012**, 109 Suppl 1, 7-16	5.6	87
72	Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy. *Therapeutic Advances in Urology*, **2012**, 4, 155-60	3.2	12
71	Margin status after laparoscopic radical prostatectomy and the index lesion: implications for preoperative evaluation of tumor focality in prostate cancer. *Journal of Endourology*, **2012**, 26, 503-8	2.7	19
70	A biomedical engineering approach to mitigate the errors of prostate biopsy. *Nature Reviews Urology*, **2012**, 9, 227-31	5.5	28
69	844 PERFORMANCES OF TEMPLATE PROSTATE MAPPING (TPM) VERSUS TRANSRECTAL ULTRASOUND GUIDED (TRUS) BIOPSIES: AN ORIGINAL COMPUTER SIMULATION ON CYSTOPROSTECTOMY SPECIMENS. *Journal of Urology*, **2011**, 185,	2.5	1
68	Focal therapy for localized prostate cancer: a phase I/II trial. *Journal of Urology*, **2011**, 185, 1246-54	2.5	191
67	Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. *Urologia Internationalis*, **2011**, 87, 49-53	1.9	48
66	Characterizing clinically significant prostate cancer using template prostate mapping biopsy. *Journal of Urology*, **2011**, 186, 458-64	2.5	229
65	Re: Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. N. Lawrentschuk, A. Finelli, T. H. Van der Kwast, P. Ryan, D. M. Bolton, N. E. Fleshner, J. Trachtenberg, L. Klotz, M. Robinette and H. Woo. J Urol 2011;185: 862-868. *Journal of Urology*, **2011**, 186, 1159-60; author reply 1160-1	2.5	2
64	High-Intensity Focused Ultrasound **2011**, 106-113		1

63	Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. *BJU International*, **2011**, 107, 338	5.6	2
62	Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. *Prostate Cancer and Prostatic Diseases*, **2011**, 14, 46-52	6.2	97
61	Modelling prostate motion for data fusion during image-guided interventions. *IEEE Transactions on Medical Imaging*, **2011**, 30, 1887-900	11.7	39
60	Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. *European Urology*, **2011**, 59, 477-94	10.2	537
59	Tumor focality in prostate cancer: implications for focal therapy. *Nature Reviews Clinical Oncology*, **2011**, 8, 48-55	19.4	61
58	Time to rethink PSA screening. *Archives of Internal Medicine*, **2011**, 171, 595; author reply 595-6		1
57	Molecular Biology of Penile Cancer **2011**, 13-25		1
56	Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. *BJU International*, **2010**, 106, 991-7	5.6	67
55	The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. *BJU International*, **2010**, 106, 1607-11	5.6	106
54	Active surveillance: is there a need for better risk stratification at the outset?. *Journal of Clinical Oncology*, **2010**, 28, e513; author reply e514	2.2	7
53	Is focal therapy the future for prostate cancer?. *Future Oncology*, **2010**, 6, 261-8	3.6	16
52	Focal therapy in prostate cancer: determinants of success and failure. *Journal of Endourology*, **2010**, 24, 819-25	2.7	19
51	Conceptual basis for focal therapy in prostate cancer. *Journal of Endourology*, **2010**, 24, 811-8	2.7	24
50	Focal therapy for prostate cancer: fact or fiction?. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 550-6	2.8	8
49	Testicular and paratesticular tumours in the prepubertal population. *Lancet Oncology, The*, **2010**, 11, 476-83	21.7	83
48	Prostate High-Intensity Focused Ultrasound **2010**, 133-146		1
47	The effects of the time period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. *BJU International*, **2010**, 106, 131-2; author reply 132	5.6	7
46	Novel methods of treating early prostate cancer: cryotherapy and high-intensity focused ultrasound. *Trends in Urology Gynaecology & Sexual Health*, **2010**, 15, 27-32		

45	Photodynamic therapy for focal ablation of the prostate. *World Journal of Urology*, **2010**, 28, 571-6	4	45
44	Benchmarks for success in focal therapy of prostate cancer: cure or control?. *World Journal of Urology*, **2010**, 28, 577-82	4	15
43	A comparison of the accuracy of statistical models of prostate motion trained using data from biomechanical simulations. *Progress in Biophysics and Molecular Biology*, **2010**, 103, 262-72	4.7	12
42	Minimally Invasive Technologies in the Treatment of Renal and Prostate Cancer **2010**, 506-522		
41	The index lesion and the origin of prostate cancer. *New England Journal of Medicine*, **2009**, 361, 1704-6	59.2	257
40	Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. *Surgical Oncology*, **2009**, 18, 219-32	2.5	79
39	Molecular prognostic factors in penile cancer. *World Journal of Urology*, **2009**, 27, 161-7	4	34
38	Reply to TS Clark: High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series *British Journal of Cancer*, **2009**, 101, 2056-2056	8.7	78
37	Reply to S Eggener, M Gonzalgo and O Yossepowitch: High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series *British Journal of Cancer*, **2009**, 101, 2059-2059	8.7	78
36	Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. *BJU International*, **2009**, 103, 321-3	5.6	48
35	The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. *BJU International*, **2009**, 104, 269-70; author reply 270	5.6	6
34	High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. *BJU International*, **2009**, 104, 1170-1; author reply 1171	5.6	1
33	Is it time to consider a role for MRI before prostate biopsy?. *Nature Reviews Clinical Oncology*, **2009**, 6, 197-206	19.4	247
32	High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. *British Journal of Cancer*, **2009**, 101, 19-26	8.7	108
31	MR to ultrasound image registration for guiding prostate biopsy and interventions. *Lecture Notes in Computer Science*, **2009**, 12, 787-94	0.9	13
30	The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. *BJU International*, **2008**, 102, 786-92	5.6	94
29	Nanotechnology in the management of prostate cancer. *BJU International*, **2008**, 102, 1493-5	5.6	8
28	Tissue Characterisation in Prostate Cancer Using a Novel Ultrasound Approach. *British Journal of Medical and Surgical Urology*, **2008**, 1, 98-106		3

27	Is there a role for magnetic resonance imaging in diagnosing colovesical fistulas?. *Urology*, **2008**, 72, 832-7	1.6	26
26	TRANSRECTAL HIGH INTENSITY FOCUSED ULTRASOUND IN THE TREATMENT OF LOCALISED PROSTATE CANCER THE FIRST UK SERIES. *Journal of Urology*, **2008**, 179, 493-493	2.5	3
25	Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. *Journal of Urology*, **2008**, 180, 780-1; author reply 781-3	2.5	8
24	PROSTATE CANCER RISK STRATIFICATION AND CANCER MAPPING TEMPLATE TRANSPERINEAL PROSTATE MAPPING BIOPSIES. *Journal of Urology*, **2008**, 179, 155-155	2.5	4
23	Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?. *World Journal of Urology*, **2008**, 26, 457-67	4	37
22	Modelling Prostate Gland Motion for Image-Guided Interventions. *Lecture Notes in Computer Science*, **2008**, 79-88	0.9	5
21	A statistical motion model based on biomechanical simulations for data fusion during image-guided prostate interventions. *Lecture Notes in Computer Science*, **2008**, 11, 737-44	0.9	6
20	Re: Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau and L. Lemaitre, J Urol 2006; 176: 2432-2437. *Journal of Urology*, **2007**, 177, 2395; author reply 2395-6	2.5	5
19	The phosphodiesterase inhibitors and non-arteritic anterior ischaemic optic neuropathy: increased vigilance is necessary. *BJU International*, **2007**, 100, 3-4	5.6	3
18	Nanotechnology and its relevance to the urologist. *European Urology*, **2007**, 52, 368-75	10.2	15
17	Will focal therapy become a standard of care for men with localized prostate cancer?. *Nature Clinical Practice Oncology*, **2007**, 4, 632-42		137
16	Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. *Tumor Biology*, **2007**, 28, 123-31	2.9	65
15	Greenlight prostatectomy: a challenge to the gold standard? A review of KTP photoselective vaporization of the prostate. *Surgical Laparoscopy, Endoscopy and Percutaneous Techniques*, **2007**, 17, 156-63	1.3	16
14	An update on the management of Wilms' tumour. *European Journal of Surgical Oncology*, **2007**, 33, 824-31	3.6	13
13	Molecular and genetic pathways in penile cancer. *Lancet Oncology, The*, **2007**, 8, 420-9	21.7	78
12	Part I: Primary malignant non-Wilms' renal tumours in children. *Lancet Oncology, The*, **2007**, 8, 730-7	21.7	60
11	Part II: Treatment of primary malignant non-Wilms' renal tumours in children. *Lancet Oncology, The*, **2007**, 8, 842-8	21.7	40
10	Diagnosis and management of renal (ureteric) colic. *British Journal of Hospital Medicine (London, England: 2005)*, **2006**, 67, 465-9	0.8	3

9	Management of detrusor-external sphincter dyssynergia. *Nature Reviews Urology*, **2006**, 3, 368-80		34
8	Nanotechnology: potential applications in urology. *BJU International*, **2006**, 98, 231-2	5.6	1
7	The intravenous urogram. *British Journal of Hospital Medicine (London, England: 2005)*, **2006**, 67, M170-2	0.8	
6	Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets. *Expert Review of Anticancer Therapy*, **2005**, 5, 1011-22	3.5	0
5	First aid and cardiopulmonary resuscitation training for medical students. *Medical Education*, **2004**, 38, 913	3.7	3
4	Acute abdomen from a Meckel lipoma. *Journal of the Royal Society of Medicine*, **2004**, 97, 288-9	2.3	3
3	Acute abdomen secondary to a Meckel's lipoma. *Annals of the Royal College of Surgeons of England*, **2004**, 86, W4-5	1.4	3
2	Cholecystectomy in patients with previous spinal cord injury. *American Journal of Surgery*, **2002**, 184, 452-9	2.7	7
1	Evaluating Focal Therapy: Future Perspectives170-177		